we plan to include immunocytochemical analysis of progesterone receptor , or pr , proteins as part of the target-selector ctc menu in 2017. a patient 's her2 status provides the physician with information about the appropriateness of therapies such as herceptin ® or tykerb ® . er and pr status provides the physician with information about the appropriateness of endocrine therapies such as tamoxifen and aromatase inhibitors . the lung cancer biomarker analyses currently include fish testing for alk , ros1 , ret , met and fgfr1 gene rearrangements and mutation analysis of the t790m , deletion 19 , and l858r mutations of the epidermal growth factor receptor , or egfr , gene as well as braf and kras using our target-selector ctdna platform . the l858r mutation of the egfr gene and exon 19 deletions as activators of egfr kinase activity are associated with the drugs tarceva ® , gilotrif ® and iressa ® . for lung cancer , we also offer a resistance profile assay consisting of the biomarkers met , her2 ( both of which we perform using our technology for ctcs ) , kras , and t790m ( both of which are performed using ctdna in plasma ) . this 63 assay could be used by physicians to identify the mechanism causing disease progression for patients with nsclc who are be ing treated with tki therapy and therefore could qualify for inclusion in a clinical trial . in november 2015 , tagrisso ® was approved by the u.s. food and drug administration , providing another biomarker-based therapy for the treatment of patients with egfr related lung cancer . tagrisso ® is indicated for the treatment of patients with metastatic egfr t790m mutation-positive nsclc , who have progressed on or after egfr tyrosine kinase inhibitor therapy . fibroblast growth receptor 1 , or fgfr1 , amplification is offered using our ctc technology . fgfr1 is present in several tumor types , including both nsclc and sclc and has been shown to be a prognostic indicator of progression . fgfr1 is also a key target for many drugs which are in clinical development . mutations of the braf gene are associated with zelboraf ® and tafinlar ® , which are both approved for treating patients with melanoma and are in clinical trials for lung cancer . we offer testing for braf on blood using our ctdna offering . we analytically validated pd-l1 testing utilizing our ctc technology in 2016. pd-l1 is a biomarker that is informative for immuno-oncology therapies currently marketed today for lung cancer and melanoma , as well as for therapies in development for multiple tumor types . we collaborated with david rimm , m.d . , ph.d. , a pathologist at yale medical school , on the analytical development of this assay . we plan to add other biomarker analyses , such as esr1 and nras , on blood samples to our current assays and our planned future target-selector assays as their relevance is demonstrated in clinical trials and or included in guidelines used by physicians to make treatment decisions . in addition , we plan to offer multiplexed assays which allow the detection and quantification of multiple biomarkers in a single assay . we continue to execute on our strategies intended to expand our business globally as well as engaging with pharmaceutical companies on clinical trials and assay development . we have executed distribution agreements in mexico with quest diagnostics to support testing for a large pharmaceutical partner , as well as an agreement with progenetics to market our assays in israel for clinical testing . in addition , we have distribution agreements in place in turkey , the czech republic , the philippines , peru , columbia and canada . we announced three additional pharmaceutical collaborations during 2016. the first agreement is to provide testing for a clinical trial that includes patients who have leptomeningeal disease or metastatic lung cancer in the brain . in this exploratory trial , we are testing both cerebral spinal fluid and blood for molecular alterations that could be impacted by treatment . the second agreement is a large milestone-based multi-project assay development collaboration focused on multiple tumor types including breast cancer and on multiple tumor types including breast cancer and hepatocellular carcinoma , or liver cancer , whereby we intend to develop assays utilizing both our ctc and ctdna technologies for clinical trials . the third collaboration involves a study presented at the european society for medical oncology , or esmo , annual congress in october 2016 , whereby collaborators from a large pharmaceutical company , and academic investigators , demonstrated a high concordance between our target-selector liquid biopsy and tissue biopsy . subsequent to this study , we have earned business in both mexico and columbia for egfr testing in blood to qualify patients for a pharmaceutical company 's targeted therapy . our revenue generating efforts are focused in three areas : providing clinical testing that oncologists use in order to determine the best treatment plan for their patients ; providing clinical trial , research and development services to biopharma companies developing cancer therapies ; and licensing our proprietary testing and or technologies to partners in the united states and abroad . key factors affecting our results of operations and financial condition our overall long-term growth plan depends on our ability to continue to develop and commercialize assays through our clia-certified , cap-accredited , and state-licensed laboratory . we have launched our target-selector offering for breast cancer , lung cancer , gastric cancer , colorectal cancer , prostate cancer , and melanoma , and plan to continue to launch a series of cancer diagnostic assays for different predictive biomarkers assays in the united states as ldts performed in our laboratory , and enhance revenue for these products through the efforts of our sales and marketing organization , which we plan to expand . story_separator_special_tag as a result , we have estimated that the use of our net operating loss is limited and the remaining net operating loss carryforwards and research and development credits we estimate can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero . inflation we do not believe that inflation has had a material adverse impact on our business or operating results during the periods presented . story_separator_special_tag style= `` background-color : # ffffff ; margin-bottom:0pt ; margin-top:18pt ; text-indent:0 % ; font-weight : bold ; font-style : italic ; color : # 000000 ; font-size:10pt ; font-family : times new roman ; text-transform : none ; font-variant : normal ; `` > debt financing on april 30 , 2014 , we received net cash proceeds of approximately $ 4,898,000 pursuant to the execution of the april 2014 credit facility with oxford finance llc . upon the entry into the april 2014 credit facility , we were required to pay the lender a facility fee of $ 50,000 in conjunction with the funding of the term loan . the april 2014 credit facility is secured by substantially all of our personal property other than our intellectual property . amounts due to oxford finance llc under the april 2014 credit facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement , including changes deemed to be materially adverse by the lender . the term loan under the april 2014 credit facility bears interest at an annual rate equal to the greater of ( i ) 7.95 % or ( ii ) the sum of ( a ) the three-month u.s. libor rate reported in the wall street journal three business days prior to the funding date of the term loan , plus ( b ) 7.71 % . the term loan bears interest at an annual rate of 7.95 % . we were required to make interest-only payments on the term loan 70 through august 1 , 2015. the outstanding term loan under the april 2014 credit facility began amortizing at the end of the applicable interest-only period , with monthly payments of principal and interest being made by us to the lender in consecutive monthly installments following such interest-only period . the term loan under the april 2014 credit facility matures on july 1 , 2018. under the original terms of the underlying agreement , we are also required to make a final payment to the lender equal to 5.5 % of the original principal amount of the term loan funded . at our option , we may prepay the outstanding principal balance of the term loan in whole but not in part , subject to a prepa yment fee of 1 % of any amount prepaid . on june 30 , 2016 , we entered into an amendment of the april 2014 credit facility . this amendment required us to make interest-only payments on the term loan from july 1 , 2016 through september 30 , 2016 , and also requires an additional final payment of $ 50,000 to the lender . the terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period , with monthly payments of principal and interest , in arrears , being made by us to the lender in consecutive monthly installments following such interest-only period . additionally , pursuant to the amendment the aggregate outstanding principal amount of our permitted indebtedness , consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time , was increased to $ 1.2 million . the june 30 , 2016 amendment of our april 2014 credit facility was accounted for as a modification of debt under applicable accounting guidance . the april 2014 credit facility includes affirmative and negative covenants applicable to us and any subsidiaries created in the future . the affirmative covenants include , among others , covenants requiring us to maintain our legal existence and governmental approvals , deliver certain financial reports and maintain insurance coverage . the negative covenants include , among others , restrictions on transferring collateral , incurring additional indebtedness , engaging in mergers or acquisitions , paying dividends or making other distributions , making investments , creating liens , selling assets , and suffering a change in control , in each case subject to certain exceptions . the april 2014 credit facility also includes events of default , the occurrence and continuation of which provide oxford finance llc , as collateral agent , with the right to exercise remedies against us and the collateral securing the term loan under the april 2014 credit facility , including foreclosure against our properties securing the april 2014 credit facility , including our cash . these events of default include , among other things , our failure to pay any amounts due under the april 2014 credit facility , a breach of covenants under the april 2014 credit facility , insolvency , a material adverse change , the occurrence of any default under certain other indebtedness in an amount greater than $ 250,000 , and a final judgment against us in an amount greater than $ 250,000. a warrant to purchase up to 17,655 shares of our common stock at an exercise price of $ 14.16 per share with a term of 10 years was issued to oxford finance llc on april 30 , 2014. issuance costs of $ 102,498 associated with the term loan under the april 2014 credit facility were recorded as a discount to outstanding debt as of the closing date , resulting in net proceeds of $ 4,897,502. the estimated fair value of the warrant issued of $ 233,107 was also recorded as a discount to outstanding debt as of the closing date . the discounts and other issuance costs are amortized to interest expense utilizing the

liquidity and capital resources we are actively working to improve our financial position and enable the growth of our business , by raising new capital and generating revenues . equity financings pursuant to an underwriting agreement dated february 9 , 2015 between us , aegis capital corp. and feltl and company , inc. , as underwriters named therein , a public offering of 2,666,666 shares of our common stock and warrants to purchase up to an aggregate of 2,666,666 shares of our common stock was effected at a combined offering price of $ 3.75. the estimated grant date fair value of these warrants of $ 7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering . all warrants sold in this offering have a per share exercise price of $ 4.68 , are exercisable immediately and expire five years from the date of issuance . the closing of the sale of these securities to the underwriters occurred on february 13 , 2015 , when we received $ 8.8 million of net cash proceeds . additionally , the underwriters were granted a 45-day option to purchase up to 400,000 additional shares of common stock at a price of $ 3.75 per share and or additional warrants to purchase up to 400,000 shares of common stock at a price of $ 0.0003 per warrant , less underwriting discounts and commissions , to cover overallotments , if any , which was not exercised . the estimated grant date fair value of the overallotment options and warrants of $ 1.6 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering . subsequent to the closing of this offering on february 13 , 2015 , additional cash proceeds of $ 9.8 million have been received from the exercise of warrants sold in this offering . as such , the aggregate total net increase in capital related to this offering has been approximately $ 18.6 million . in may 2015 , the sec declared effective a shelf registration statement filed by us .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we are actively working to improve our financial position and enable the growth of our business , by raising new capital and generating revenues . equity financings pursuant to an underwriting agreement dated february 9 , 2015 between us , aegis capital corp. and feltl and company , inc. , as underwriters named therein , a public offering of 2,666,666 shares of our common stock and warrants to purchase up to an aggregate of 2,666,666 shares of our common stock was effected at a combined offering price of $ 3.75. the estimated grant date fair value of these warrants of $ 7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering . all warrants sold in this offering have a per share exercise price of $ 4.68 , are exercisable immediately and expire five years from the date of issuance . the closing of the sale of these securities to the underwriters occurred on february 13 , 2015 , when we received $ 8.8 million of net cash proceeds . additionally , the underwriters were granted a 45-day option to purchase up to 400,000 additional shares of common stock at a price of $ 3.75 per share and or additional warrants to purchase up to 400,000 shares of common stock at a price of $ 0.0003 per warrant , less underwriting discounts and commissions , to cover overallotments , if any , which was not exercised . the estimated grant date fair value of the overallotment options and warrants of $ 1.6 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering . subsequent to the closing of this offering on february 13 , 2015 , additional cash proceeds of $ 9.8 million have been received from the exercise of warrants sold in this offering . as such , the aggregate total net increase in capital related to this offering has been approximately $ 18.6 million . in may 2015 , the sec declared effective a shelf registration statement filed by us .
```    
 Suspicious Activity Report : we plan to include immunocytochemical analysis of progesterone receptor , or pr , proteins as part of the target-selector ctc menu in 2017. a patient 's her2 status provides the physician with information about the appropriateness of therapies such as herceptin ® or tykerb ® . er and pr status provides the physician with information about the appropriateness of endocrine therapies such as tamoxifen and aromatase inhibitors . the lung cancer biomarker analyses currently include fish testing for alk , ros1 , ret , met and fgfr1 gene rearrangements and mutation analysis of the t790m , deletion 19 , and l858r mutations of the epidermal growth factor receptor , or egfr , gene as well as braf and kras using our target-selector ctdna platform . the l858r mutation of the egfr gene and exon 19 deletions as activators of egfr kinase activity are associated with the drugs tarceva ® , gilotrif ® and iressa ® . for lung cancer , we also offer a resistance profile assay consisting of the biomarkers met , her2 ( both of which we perform using our technology for ctcs ) , kras , and t790m ( both of which are performed using ctdna in plasma ) . this 63 assay could be used by physicians to identify the mechanism causing disease progression for patients with nsclc who are be ing treated with tki therapy and therefore could qualify for inclusion in a clinical trial . in november 2015 , tagrisso ® was approved by the u.s. food and drug administration , providing another biomarker-based therapy for the treatment of patients with egfr related lung cancer . tagrisso ® is indicated for the treatment of patients with metastatic egfr t790m mutation-positive nsclc , who have progressed on or after egfr tyrosine kinase inhibitor therapy . fibroblast growth receptor 1 , or fgfr1 , amplification is offered using our ctc technology . fgfr1 is present in several tumor types , including both nsclc and sclc and has been shown to be a prognostic indicator of progression . fgfr1 is also a key target for many drugs which are in clinical development . mutations of the braf gene are associated with zelboraf ® and tafinlar ® , which are both approved for treating patients with melanoma and are in clinical trials for lung cancer . we offer testing for braf on blood using our ctdna offering . we analytically validated pd-l1 testing utilizing our ctc technology in 2016. pd-l1 is a biomarker that is informative for immuno-oncology therapies currently marketed today for lung cancer and melanoma , as well as for therapies in development for multiple tumor types . we collaborated with david rimm , m.d . , ph.d. , a pathologist at yale medical school , on the analytical development of this assay . we plan to add other biomarker analyses , such as esr1 and nras , on blood samples to our current assays and our planned future target-selector assays as their relevance is demonstrated in clinical trials and or included in guidelines used by physicians to make treatment decisions . in addition , we plan to offer multiplexed assays which allow the detection and quantification of multiple biomarkers in a single assay . we continue to execute on our strategies intended to expand our business globally as well as engaging with pharmaceutical companies on clinical trials and assay development . we have executed distribution agreements in mexico with quest diagnostics to support testing for a large pharmaceutical partner , as well as an agreement with progenetics to market our assays in israel for clinical testing . in addition , we have distribution agreements in place in turkey , the czech republic , the philippines , peru , columbia and canada . we announced three additional pharmaceutical collaborations during 2016. the first agreement is to provide testing for a clinical trial that includes patients who have leptomeningeal disease or metastatic lung cancer in the brain . in this exploratory trial , we are testing both cerebral spinal fluid and blood for molecular alterations that could be impacted by treatment . the second agreement is a large milestone-based multi-project assay development collaboration focused on multiple tumor types including breast cancer and on multiple tumor types including breast cancer and hepatocellular carcinoma , or liver cancer , whereby we intend to develop assays utilizing both our ctc and ctdna technologies for clinical trials . the third collaboration involves a study presented at the european society for medical oncology , or esmo , annual congress in october 2016 , whereby collaborators from a large pharmaceutical company , and academic investigators , demonstrated a high concordance between our target-selector liquid biopsy and tissue biopsy . subsequent to this study , we have earned business in both mexico and columbia for egfr testing in blood to qualify patients for a pharmaceutical company 's targeted therapy . our revenue generating efforts are focused in three areas : providing clinical testing that oncologists use in order to determine the best treatment plan for their patients ; providing clinical trial , research and development services to biopharma companies developing cancer therapies ; and licensing our proprietary testing and or technologies to partners in the united states and abroad . key factors affecting our results of operations and financial condition our overall long-term growth plan depends on our ability to continue to develop and commercialize assays through our clia-certified , cap-accredited , and state-licensed laboratory . we have launched our target-selector offering for breast cancer , lung cancer , gastric cancer , colorectal cancer , prostate cancer , and melanoma , and plan to continue to launch a series of cancer diagnostic assays for different predictive biomarkers assays in the united states as ldts performed in our laboratory , and enhance revenue for these products through the efforts of our sales and marketing organization , which we plan to expand . story_separator_special_tag as a result , we have estimated that the use of our net operating loss is limited and the remaining net operating loss carryforwards and research and development credits we estimate can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero . inflation we do not believe that inflation has had a material adverse impact on our business or operating results during the periods presented . story_separator_special_tag style= `` background-color : # ffffff ; margin-bottom:0pt ; margin-top:18pt ; text-indent:0 % ; font-weight : bold ; font-style : italic ; color : # 000000 ; font-size:10pt ; font-family : times new roman ; text-transform : none ; font-variant : normal ; `` > debt financing on april 30 , 2014 , we received net cash proceeds of approximately $ 4,898,000 pursuant to the execution of the april 2014 credit facility with oxford finance llc . upon the entry into the april 2014 credit facility , we were required to pay the lender a facility fee of $ 50,000 in conjunction with the funding of the term loan . the april 2014 credit facility is secured by substantially all of our personal property other than our intellectual property . amounts due to oxford finance llc under the april 2014 credit facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement , including changes deemed to be materially adverse by the lender . the term loan under the april 2014 credit facility bears interest at an annual rate equal to the greater of ( i ) 7.95 % or ( ii ) the sum of ( a ) the three-month u.s. libor rate reported in the wall street journal three business days prior to the funding date of the term loan , plus ( b ) 7.71 % . the term loan bears interest at an annual rate of 7.95 % . we were required to make interest-only payments on the term loan 70 through august 1 , 2015. the outstanding term loan under the april 2014 credit facility began amortizing at the end of the applicable interest-only period , with monthly payments of principal and interest being made by us to the lender in consecutive monthly installments following such interest-only period . the term loan under the april 2014 credit facility matures on july 1 , 2018. under the original terms of the underlying agreement , we are also required to make a final payment to the lender equal to 5.5 % of the original principal amount of the term loan funded . at our option , we may prepay the outstanding principal balance of the term loan in whole but not in part , subject to a prepa yment fee of 1 % of any amount prepaid . on june 30 , 2016 , we entered into an amendment of the april 2014 credit facility . this amendment required us to make interest-only payments on the term loan from july 1 , 2016 through september 30 , 2016 , and also requires an additional final payment of $ 50,000 to the lender . the terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period , with monthly payments of principal and interest , in arrears , being made by us to the lender in consecutive monthly installments following such interest-only period . additionally , pursuant to the amendment the aggregate outstanding principal amount of our permitted indebtedness , consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time , was increased to $ 1.2 million . the june 30 , 2016 amendment of our april 2014 credit facility was accounted for as a modification of debt under applicable accounting guidance . the april 2014 credit facility includes affirmative and negative covenants applicable to us and any subsidiaries created in the future . the affirmative covenants include , among others , covenants requiring us to maintain our legal existence and governmental approvals , deliver certain financial reports and maintain insurance coverage . the negative covenants include , among others , restrictions on transferring collateral , incurring additional indebtedness , engaging in mergers or acquisitions , paying dividends or making other distributions , making investments , creating liens , selling assets , and suffering a change in control , in each case subject to certain exceptions . the april 2014 credit facility also includes events of default , the occurrence and continuation of which provide oxford finance llc , as collateral agent , with the right to exercise remedies against us and the collateral securing the term loan under the april 2014 credit facility , including foreclosure against our properties securing the april 2014 credit facility , including our cash . these events of default include , among other things , our failure to pay any amounts due under the april 2014 credit facility , a breach of covenants under the april 2014 credit facility , insolvency , a material adverse change , the occurrence of any default under certain other indebtedness in an amount greater than $ 250,000 , and a final judgment against us in an amount greater than $ 250,000. a warrant to purchase up to 17,655 shares of our common stock at an exercise price of $ 14.16 per share with a term of 10 years was issued to oxford finance llc on april 30 , 2014. issuance costs of $ 102,498 associated with the term loan under the april 2014 credit facility were recorded as a discount to outstanding debt as of the closing date , resulting in net proceeds of $ 4,897,502. the estimated fair value of the warrant issued of $ 233,107 was also recorded as a discount to outstanding debt as of the closing date . the discounts and other issuance costs are amortized to interest expense utilizing the

